Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000872 · ClinicalTrials.gov registry record · Phase 2
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00000872 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 55 participants.
The verdict
NCT00000872, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.
Interventions
- DRUG Lamivudine
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Nevirapine
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000872
The ClinicalTrials.gov registry entry for NCT00000872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00000872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000872 about?
NCT00000872 is a clinical study titled "Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection". This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to ...
What is the current status of trial NCT00000872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00000872?
The interventions under investigation include: Lamivudine (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Nevirapine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00000872?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.